Novartis begins more Phase III biosimilar studies of Amgen drugs Pharma Times Ameet Mallik, head of Sandoz biopharmaceuticals, added that a late-stage trials for a biosimilar of Roche's Rituxan (rituximab) is ongoing and the pipeline, consists of eight-10 copycat biologics. |
